Dr. Ramaa P Rao, M.D. Obstetrics & Gynecology - Reproductive Endocrinology Medicare: Not Enrolled in Medicare Practice Location: 3703 W Lake Ave, Suite 310 Attn Fci, Glenview, IL 60026 Phone: 847-729-2188 Fax: 847-729-2396 |
Dr. Brian R Kaplan, M.D. Obstetrics & Gynecology - Reproductive Endocrinology Medicare: Not Enrolled in Medicare Practice Location: 2555 Patriot Blvd Ste 100, Glenview, IL 60026 Phone: 847-998-8200 |
Dr. Laurence A Jacobs, M.D. Obstetrics & Gynecology - Reproductive Endocrinology Medicare: Not Enrolled in Medicare Practice Location: 2555 Patriot Blvd Ste 100, Glenview, IL 60026 Phone: 847-729-2188 |
Jeremy Miller, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 3633 W Lake Ave, 204, Glenview, IL 60026 Phone: 847-729-2240 |
Elena Bryce, Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 2701 Patriot Blvd, Glenview, IL 60026 Phone: 650-498-7570 Fax: 847-998-9303 |
News Archive
Scientists have automated the measurement of a vital part of the knee in images with a computer program that performs much faster and just as reliably as humans who interpret the same images.
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced that it intends to offer and sell, subject to market and other conditions, $150,000,000 of shares of its common stock in an underwritten public offering.
"The framework for antibiotic discovery, development and approval is broken," Matthew Cooper of the University of Queensland and David Shales, former vice president at Wyeth Pharmaceuticals, write in a Nature comment, calling for "a sustained effort from government and industry to develop new drugs quickly."
No cures are possible for most patients who suffer debilitating movement disorders called cerebellar ataxias. But in a few of these disorders, patients can be effectively treated with regimens such as prescription drugs, high doses of vitamin E and gluten-free diets, according to a study in the journal Movement Disorders.
PolyMedix, Inc., an emerging biotechnology company developing acute care products for infectious diseases and acute cardiovascular disorders, has successfully completed the first two segments of a Phase 1B clinical safety study with its novel antibiotic drug candidate PMX-30063.
› Verified 9 days ago